Low ferritin levels can affect hair density, and increasing ferritin through iron supplements may help with regrowth. It's suggested to maintain ferritin levels between 70-100 ng/mL and check other micronutrients for optimal hair health.
Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.
Treatments for hair loss, specifically the use of minoxidil, finasteride and RU58841. Replies to this post suggest that users should share relevant information publicly rather than through direct messages.
Homemade topical finasteride solutions are discussed, with one user using 30% ethanol, 50% propylene glycol, and 20% water. Alternatives like dissolving finasteride pills in minoxidil and using stemoxydine are also mentioned.
The user shared their bloodwork results showing DHT at 17 ng/dl and testosterone at 287 ng/dl, with a slight Vitamin D deficiency. They are seeking opinions on these levels and have an upcoming dermatologist appointment.
Topical finasteride may have higher systemic absorption and lower efficacy when using a Propylene Glycol/Ethanol formulation compared to the hydroxypropyl chitosan (HPCH) formulation. The safety profile of topical finasteride relies heavily on the HPCH formulation, and using standard solutions might lead to different pharmacokinetics.
Diffuse thinners find shopping challenging due to harsh overhead lighting, but H&M's side lighting in fitting rooms is more flattering. Many users humorously suggest banning overhead lighting to improve the shopping experience.
RU58841 is being mixed with Minoxidil solution, but concerns arise about water causing instability. Mixing with water may lead to hydrolysis, potentially reducing effectiveness.
There is an inconsistency between the molecular weight and formula listed on EveryChem's product page and the analytical PDFs for 3HP and PP30, suggesting a possible error in the product description. Concerns are raised about EveryChem's business practices and lack of transparency in testing and manufacturing.
Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115 release timeline is uncertain, with possible grey market availability in 2024-2025.
The conversation is about making a 20mg/ml RU58841 solution for hair loss treatment using ethanol and propylene glycol. The user receives advice on calculating the correct amount of RU58841 powder needed.
Creatine monohydrate's potential link to hair loss, with mixed opinions on its effects. Treatments like minoxidil, finasteride, and RU58841 are discussed.
The user experienced side effects from oral finasteride and tried mixing it with liquid minoxidil but faced application issues. They are seeking a 5% minoxidil foam with a maximum of 0.15% topical finasteride concentration.
Creatine does not increase DHT levels, but some report hair loss when using it, possibly due to other factors. The effects on hair loss vary individually, with no clear connection established.
The user experienced scalp irritation from a Finasteride and Minoxidil spray and serum. They are considering switching to foam, oral treatments, or another provider.
The user shared their positive experience with a hair loss treatment regimen, which includes a diluted version of Hims finasteride spray, Kirkland 5% minoxidil, and weekly dermarolling. The user also mentioned taking hair multivitamins and plans to continue updating on their progress.
The conversation discusses how the absorption rate of topical finasteride varies and is not equivalent to its oral form, with only a small percentage reaching the scalp. It also mentions that minoxidil in high concentrations is used topically because only a small amount is absorbed.
OP wants to increase pyrilutamide concentration from 0.5% to 1% while already using finasteride. Users suggest waiting for a commercial 1% solution and caution against using grey market products.
Imidazole drugs like ketoconazole inhibit certain enzymes and prevent DHT from binding to SHBG, increasing free DHT in the bloodstream, which may contribute to balding. The discussion questions how these drugs help with hair loss despite this effect.
The conversation discusses using Sandalore for hair loss treatment, with a focus on finding the correct concentration for a topical lotion. The consensus is to start with a 0.1% concentration due to potential scalp irritation at higher levels.
The conversation discusses hair loss treatments, specifically minoxidil, vitamin D supplements, and the potential impact of iron overload. The user experienced hair regrowth with high-dose vitamin D but faced hair thinning again after reducing the dosage, and is now exploring the role of iron overload in hair loss.
The user plans to test for DHT, total testosterone, free testosterone, E2, SHBG, and prolactin while supplementing with vitamin D and monitoring ferritin levels. They are experiencing hairline thinning and are seeking advice on whether their approach is excessive or lacking.
The conversation discusses the HMI-115 trial for hair loss, which was expected to end around July 2023 due to a late participant. Participants also mention Minoxidil, finasteride, and RU58841 as treatments.
The conversation discusses the effects of lowering DHT on hair loss and the importance of monitoring DHT levels during treatment. The user suggests that individual responses to DHT and hair loss treatments vary, and expresses a preference for topical treatments over oral medications due to concerns about systemic DHT reduction.
A user who didn't respond well to minoxidil and finasteride is considering the role of IGF-1 in hair loss treatment effectiveness. They discuss the potential of using HGH to improve hair growth and other health issues, referencing several sources that suggest IGF-1 levels may influence hair loss and treatment response.
PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.